VIP Research History: Discovery, Key Studies and Regulatory Timeline

What This Page Covers

This page assembles the research history of vasoactive intestinal peptide (VIP) as it appears in the published, citable literature: how the peptide is described at its origin, which papers mark the main turning points, and what the record does and does not say about regulatory status. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question. No dose, protocol or outcome is recommended anywhere below, and every date attached to a finding is the publication date of the paper linked in the same sentence.

One editorial rule shapes this history: a year is stated only when a cited paper carries it. Where the record reviewed here does not date an event, the page says so rather than filling the gap. Readers looking for a general orientation to the peptide rather than its chronology can consult the VIP overview page at /learn/vip/.

Discovery: What the Published Record Describes

A gut peptide named for what it did

The name itself records the discovery context. Reviews of VIP biology describe the peptide as an intestinal product characterised originally through its vascular actions and subsequently found far beyond the gut, with the 2004 Pharmacological Reviews survey describing VIP as a widely distributed peptide whose significance extends into immunomodulation rather than digestion alone (PMID 15169929). A 2003 review in Trends in Molecular Medicine similarly framed VIP, alongside the related peptide PACAP, as endogenous mediators whose immune actions had become the dominant research question of that period (PMID 12763526).

Two features recur across the early descriptive literature. First, VIP is characterised as a neuropeptide as much as a gut hormone: a 2012 review in Endocrine, Metabolic & Immune Disorders Drug Targets was titled, explicitly, "VIP in neurological diseases: more than a neuropeptide" (PMID 23094829). Second, VIP is repeatedly described as a trophic or growth-influencing factor, a theme set out in a 2003 Peptides review of VIP as a trophic factor in the central nervous system and in cancer cells (PMID 12576099).

The peptide family and its receptors

A second strand of discovery history concerns the family VIP belongs to. A 2018 review in The Journal of Headache and Pain recounted the discovery of pituitary adenylate cyclase-activating polypeptide (PACAP) and of its receptors in the brain, describing a closely related peptide that shares receptor targets with VIP (PMID 29619773). That shared pharmacology is why much of the subsequent literature is written as "VIP and PACAP" rather than about either peptide alone, a convention visible in a 2015 Peptides review of PACAP and VIP signalling in chondrogenesis and osteogenesis (PMID 25701761).

Chronological Map of the Cited Literature

The 2000s: The Immunomodulation Era

If the first decades of VIP research established where the peptide was found, the early 2000s established what researchers thought it was doing in immune tissue. The 2003 Trends in Molecular Medicine review presented VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools, the word choice is the authors' own framing of an early-stage field rather than a claim of established benefit (PMID 12763526). The following year, a far longer treatment in Pharmacological Reviews consolidated the immunomodulation literature into a single reference work on the significance of VIP in immune regulation (PMID 15169929).

Running in parallel was the trophic-factor literature. The 2003 Peptides review examined VIP both as a growth-influencing signal in the central nervous system and as a factor interacting with cancer cells, a dual framing that researchers have returned to repeatedly since (PMID 12576099). Readers tracing the history should note that these were narrative reviews rather than clinical trials; they describe mechanisms and hypotheses, not outcomes in treated populations.

Formulation and Delivery Research

A practical obstacle shaped the field's direction: peptides of this class are short-lived in circulation, and much of the methodological literature addresses delivery rather than biology. A 2005 chapter in Methods in Enzymology set out laboratory methods for liposomal vasoactive intestinal peptide, describing how the peptide was associated with liposome carriers for experimental work (PMID 15721392). That paper is a methods source, not an efficacy study, and it is cited here only for what it is: evidence that formulation science was an active part of the VIP research programme by the mid-2000s.

The 2010s: Neurological and Skeletal Biology

The 2012 review in Endocrine, Metabolic & Immune Disorders Drug Targets gathered the neurological literature, arguing that VIP's role in nervous-system disease extended beyond classical neurotransmission (PMID 23094829). Three years later, a 2015 Peptides review moved the family into skeletal biology, surveying PACAP and VIP signalling in chondrogenesis and osteogenesis, cartilage and bone formation, and treating the two peptides as a coupled signalling system (PMID 25701761).

The decade closed with a historical review of its own: the 2018 account of how PACAP and its brain receptors were discovered, published in a headache journal because of the peptide family's links to cranial vascular signalling (PMID 29619773). For anyone reconstructing VIP's timeline, that paper is the most explicitly historical document in the verified set.

The 2020s: Circuits, Lungs, Retina and Addiction Targets

VIP-expressing neurons as a cell type

A notable shift in the current decade is that "VIP" increasingly names a cell population rather than only a molecule. A 2021 review in Developmental Neuroscience examined VIP interneurons and their proposed role in neurodevelopmental disorders, treating VIP expression as a marker defining a cortical interneuron class (PMID 33794534). In the visual system, a 2024 review in Eye described the development, structure and function of retinal VIP-amacrine cells, another VIP-defined population (PMID 38066110).

Respiratory research

Lung biology has been one of the most active areas. A 2023 review in Life Sciences surveyed the role of VIP across pulmonary diseases, drawing together airway, vascular and inflammatory strands of the literature (PMID 37742737). In 2025, a primary research paper in Immunity reported that nociceptor neurons suppressed alveolar macrophage-induced, Siglec-F-positive neutrophil-mediated inflammation, with that neuro-immune circuit protecting against pulmonary fibrosis in the models studied (PMID 40449484). That paper marks the current frontier of the field: sensory-neuron peptide signalling examined as a control point on lung inflammation.

Addiction pharmacology

A 2024 review in Alcohol catalogued emerging pharmacological targets for alcohol use disorder, placing neuropeptide systems among the candidate mechanisms under investigation (PMID 39069210). The study category here matters: this is a target-identification review describing where research is heading, not a report of treatment outcomes.

Regulatory Timeline: What the Cited Record Does and Does Not State

Readers searching for an approval date should understand what the citable evidence on this page supports. None of the verified publications listed above is a regulatory document, and none reports a marketing-authorisation decision for VIP. The 2003 immunomodulation review described VIP and PACAP as prospective therapeutic tools (PMID 12763526), and the 2023 pulmonary review likewise framed VIP as a subject of investigation across lung disease rather than as an established therapy (PMID 37742737). On that evidence base, the honest summary is that the literature reviewed here documents a research programme, not an approved product history.

Two general regulatory facts are worth stating without attaching them to any of these papers. Peptides supplied to laboratories are commonly labelled research use only (RUO), meaning they are not represented as medicines for human or veterinary administration. Separately, national medicines regulators maintain their own public approval databases, and those databases, not review articles, are the authoritative source for whether a specific product containing a peptide has been authorised, for what indication, and on what date. Nothing on this page is legal or regulatory advice.

Adverse Events in VIP Research: What Studies Report

The verified publications assembled here are predominantly narrative reviews, methods chapters and preclinical research papers, and none of them is a safety study with pooled tolerability data. The 2004 Pharmacological Reviews article addressed immunomodulatory significance rather than a structured adverse-event profile (PMID 15169929), and the 2023 Life Sciences pulmonary review likewise discussed disease mechanisms rather than tolerability outcomes (PMID 37742737). The 2003 trophic-factor review raised a different kind of biological caution by examining VIP's interactions with cancer cells alongside its central-nervous-system actions (PMID 12576099). Where a page's citation set contains no human safety trial, the correct statement is that no adverse-event frequencies can be quoted from it, not that none exist.

How to Read This History

• Reviews are not trials. Most of the papers above synthesise prior work; they describe hypotheses and mechanisms, and they do not establish clinical outcomes (PMID 15169929).
• Preclinical findings are species- and model-specific. The 2025 Immunity paper reported a neuro-immune mechanism in experimental pulmonary fibrosis, which is a different claim from a demonstrated human treatment effect (PMID 40449484).
• "VIP" can mean a peptide or a cell type. Interneuron and amacrine-cell papers use VIP as an expression marker (PMID 33794534, PMID 38066110).
• VIP and PACAP travel together. Shared receptors mean family-level reviews often cover both (PMID 29619773, PMID 25701761).

References

• VIP as a trophic factor in the CNS and cancer cells (Peptides, 2003)
• VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools (Trends in Molecular Medicine, 2003)
• The significance of vasoactive intestinal peptide in immunomodulation (Pharmacological Reviews, 2004)
• Liposomal vasoactive intestinal peptide (Methods in Enzymology, 2005)
• VIP in neurological diseases: more than a neuropeptide (Endocrine, Metabolic & Immune Disorders Drug Targets, 2012)
• PACAP and VIP signaling in chondrogenesis and osteogenesis (Peptides, 2015)
• Discovery of PACAP and its receptors in the brain (The Journal of Headache and Pain, 2018)
• A Role for Vasoactive Intestinal Peptide Interneurons in Neurodevelopmental Disorders (Developmental Neuroscience, 2021)
• The role of vasoactive intestinal peptide in pulmonary diseases (Life Sciences, 2023)
• Retinal VIP-amacrine cells: their development, structure, and function (Eye, 2024)
• Emerging pharmacological targets for alcohol use disorder (Alcohol, 2024)
• Nociceptor neurons suppress alveolar macrophage-induced Siglec-F(+) neutrophil-mediated inflammation to protect against pulmonary fibrosis (Immunity, 2025)